International Experts Recommend Ending Routine 'Corrected' Calcium Reporting

For decades, laboratories have used formulas to adjust total calcium for albumin, but growing evidence shows that these corrections often perform poorly and may contribute to patient harm. International experts now recommend ending routine albumin-adjusted calcium reporting and prioritizing measurements that better reflect contemporary understanding of calcium physiology.

The recommendation is outlined in a new position statement, “Albumin-adjusted (‘corrected’) calcium should no longer be reported,” published in Clinical Chemistry and Laboratory Medicine. The statement was developed by a working group representing the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Committee on Chronic Kidney Disease, the Joint International Osteoporosis Foundation (IOF) Working Group, and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Bone Metabolism. The document urges clinical laboratories to discontinue automatic reporting of albumin-adjusted calcium. It emphasizes that ionized calcium is the biologically active fraction and should inform decisions when calcium status is clinically pivotal or ambiguous.

The statement explains that “correction” relies on mathematical formulas that estimate calcium bound to albumin in order to approximate physiologically active calcium. According to the expert groups, these formulas frequently underperform in patients with chronic illness, chronic kidney disease, inflammation, acid–base disturbances, or low albumin. They also note added analytical uncertainty and poor standardization across laboratories, because results depend on local albumin methods and patient populations.

Citing recent large-scale studies, the authors state that unadjusted total calcium often aligns more closely with ionized calcium than commonly used correction formulas, which may falsely normalize true hypocalcemia or suggest hypercalcemia. The guidance recommends reporting total calcium as the default result, ordering ionized calcium when interpretation is clinically important or difficult, and using ionized calcium as the first-line test in severe hypoalbuminemia or dialysis patients, provided appropriate sampling and quality standards are met.

Because calcium balance directly informs therapy in advanced chronic kidney disease, including the use of vitamin D analogs, calcimimetics, phosphate binders, and dialysis prescriptions, the authors also highlight substantial international variation in current practice and call for greater consistency across laboratories.

“Albumin-adjusted calcium has become deeply embedded in clinical practice despite limited validation against ionized calcium, which is the biologically active form. Current evidence indicates that these corrections can actually worsen diagnostic accuracy and mask clinically important abnormalities,” said Professor Etienne Cavalier, University of Liège and Chair of the Joint IOF Working Group and IFCC Committee on Bone Metabolism.

Related Links
Joint IOF Working Group and IFCC Committee on Bone Metabolism
EFLM Committee on Chronic Kidney Disease